MOR News and Press, MorphoSys AG From 04/29/24

– Entered into Business Combination Agreement to be acquired by Novartis for € 68.00 per share in cash, representing a total equity value of € 2.7 billion – Received all mandatory antitrust approvals for the proposed acquisition by Novartis – S...

2024-04-28 20:52:48 ET More on MorphoSys MorphoSys AG (MOR) Q4 2023 Earnings Call Transcript Novartis And MorphoSys Are A Perfect Match Novartis commences tender offer for MorphoSys MorphoSys gains after gaining U.S. antitrust approval for sale to Novartis ...

2024-04-27 15:39:17 ET More on Amgen, Cullinan Oncology, etc. Amgen: I Prefer To Chase Value And Dividends Amgen: The Giant With An Impressive Pipeline Move Over Eli Lilly: Amgen Could Be The Next Obesity Wonder Stock Cullinan Therapeutics expands into autoim...

2024-04-25 17:49:16 ET Summary The Annual Meeting of the American Society of Clinical Oncology is a major event for clinicians and researchers in the field of oncology. The plenary session will feature presentations on topics such as esophageal cancer, melanoma, and lung cancer. ...

Additional ASCO 2024 poster presentation will include new findings from the Phase 2 study of tulmimetostat PLANEGG and MUNICH, GERMANY / ACCESSWIRE / April 24, 2024 / MorphoSys AG (FSE:MOR)(NASDAQ:MOR) today announced that new efficacy and safety data from the Phase 3 MANIFEST-2 trial of pel...

Novartis offers € 68.00 per share in cash, representing a total equity value of € 2.7 billion Shareholders benefit from attractive premium of 94% and 142% on the volume-weighted average price during the last month and three months before January 25, 2024, respectively ...

2024-04-11 05:46:53 ET Novartis ( NYSE: NVS ) has commenced its tender offer to acquire all outstanding shares of German cancer drugmaker MorphoSys ( NASDAQ: MOR ) for an offer price of EUR 68 a share or €2.7B aggregate in cash.... Read the full article on S...

2024-03-22 10:29:19 ET More on MorphoSys MorphoSys AG (MOR) Q4 2023 Earnings Call Transcript Novartis And MorphoSys Are A Perfect Match MorphoSys: Positive Pelabresib Data Finally Unlocking Upside MorphoSys ADRs gain after definitive merger agreement with Nov...

PLANEGG and MUNICH, GERMANY / ACCESSWIRE / March 22, 2024 / MorphoSys AG (FSE:MOR)(NASDAQ:MOR) today announced the receipt of U.S. antitrust clearance under the Hart-Scott-Rodino Antitrust Improvements Act of 1976 (the "HSR Act") in connection with the proposed acquisition of MorphoSys by Novart...

2024-03-17 00:00:00 ET Stock Traders Daily has produced this trading report using a proprietary method.  This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...